The development of MEDFs during biologic therapy for psoriasis, including anti-IL-23 agents (ustekinumab, n = 2) (5, 6), anti-TNF-α agents (etanercept and adalimumab, n = 1) (3), and anti-CD11a therapy (efalizumab, n = 1) (7), has been reported. Here, ITGAL is linked to psoriasis.